• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: COO Walters Patrick disposed of 1,231 shares, exercised 24,063 in-the-money shares at a strike of $12.00 and sold $294,432 worth of shares (11,847 units at $24.85) (SEC Form 4)

    6/5/25 7:20:31 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WALTERS PATRICK

    (Last) (First) (Middle)
    23975 SORRENTO PARK
    SUITE 205

    (Street)
    CALABASAS CA 91302

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    COO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    03/28/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/26/2025 J(1) 1,231 D $0(2) 66,669(3) I By HCWG LLC
    Common Stock 03/26/2025 X(4) 24,063 A $12 90,732 I By HCWG LLC
    Common Stock 03/26/2025 S(5) 11,550 D $25 79,182 I By HCWG LLC
    Common Stock 03/26/2025 S 297 D $19.1299 78,885 I By HCWG LLC
    Common Stock 797,488 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrant (right to buy) $12 03/26/2025 X 24,063 03/26/2025 (6) Common Stock 24,063 $0 0 I By HCWG LLC
    Explanation of Responses:
    1. Transfer of shares of common stock held by HCWG LLC ("HCWG") pursuant to agreement.
    2. Not applicable. Number of shares transferred was based on a per share value of $18.
    3. The shares reported herein represent only Reporting Person's percentage interest in HCWG LLC.
    4. On 3/26/2025, in conjunction with Issuer's initial listing on Nasdaq, HCWG exercised a warrant to purchase 312,500 shares of Issuer's common stock at $12 per share. HCWG paid the exercise price on a cashless basis, resulting in Issuer's withholding 150,000 of the warrant shares to pay the exercise price and issuing to HCWG the remaining 162,500 shares of common stock. Number of shares reported herein as acquired and disposed of by the Reporting Person represents Reporting Person's indirect interest in HCWG.
    5. In connection with HCWG's cashless exercise of the warrant described herein, Reporting Person paid his proportionate share of the exercise price on a cashless basis. Reporting Person's proportionate withholding from shares issued to HCWG totaled 11,550 warrant shares to pay the exercise price.
    6. Not applicable.
    Remarks:
    This Form 4 Amendment is being filed to clarify that the sale of shares referenced in Row 3 of Table I was to the Issuer resulting from the cashless exercise of the warrant and no monetary consideration was received by any party therefor. See footnote 5.
    /S/ PATRICK WALTERS 06/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

      USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational

      6/6/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

      -- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position. The Company's IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally. NeOnc's expanding IP portfolio reflects its innovation engine as well as its comm

      4/15/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

      -- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target. This landmark trial, for which read-out data is expected in early 2026, investigates NEO100, a proprietary, highly purified version of perillyl alcohol, delivered intranasally, a non-invasive me

      4/14/25 8:05:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Chiang Ming-Fu (Alan) was granted 50,000 shares, disposed of 5,994 shares, exercised 117,188 in-the-money shares at a strike of $12.00 and sold $1,433,912 worth of shares (57,696 units at $24.85), increasing direct ownership by 15% to 390,216 units (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/5/25 7:25:44 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: COO Walters Patrick disposed of 1,231 shares, exercised 24,063 in-the-money shares at a strike of $12.00 and sold $294,432 worth of shares (11,847 units at $24.85) (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/5/25 7:20:31 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO Garnett Keithly disposed of 687 shares, exercised 13,438 in-the-money shares at a strike of $12.00 and sold $164,426 worth of shares (6,616 units at $24.85) (SEC Form 4)

      4/A - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      6/5/25 7:15:44 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:31:11 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:30:24 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Garnett Keithly bought $4,921 worth of shares (675 units at $7.29), increasing direct ownership by 0.28% to 240,900 units (SEC Form 4)

      4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

      5/23/25 9:28:12 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    See more
    • NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

      USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational

      6/6/25 9:00:00 AM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTHI
    SEC Filings

    See more
    • NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

      8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      6/6/25 4:59:39 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Leadership Update

      8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      6/3/25 5:00:12 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

      10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

      5/9/25 5:00:30 PM ET
      $NTHI
      Biotechnology: Pharmaceutical Preparations
      Health Care